electroCore
ROCKAWAY, NJ, United States · Healthcare, Health Care · 35 employees
ElectroCore is a medical technology company focused on developing and commercializing innovative therapies for the treatment of chronic pain and other conditions. The company is a leader in non-invasive vagus nerve stimulation and aims to enhance the quality of life for patients through its product offerings. ElectroCore has demonstrated significant revenue growth and maintains a strong market pre
Funding history
- Series seed — $1.9M — Oct 2025
- Funding Round — $7.8M — Jun 2024
- Series pre-seed — $52K — Aug 2023
- Series seed — $750K — Aug 2023
- Series pre-seed — $192K — Oct 2021
Recent signals
- Mar 19, 2026: SEC 8-K (2.02): On March 19, 2026, electroCore, Inc. announced its financial results for the year ended December 31, 2025, which included their Adjusted EBITDA and net loss from operations. The press release also provided financial guidance for the full year of 2026, indicating future expectations for the company's performance. This release is significant as it informs investors and stakeholders of the company's previous performance and future outlook, impacting investment decisions. The event date is notable for its timeliness in relation to the regulatory filing.
- Oct 17, 2025: Raised $1.9M in Series seed
- Mar 31, 2025: electroCore Extends VA Contract for Five Years
- Feb 19, 2025: Launched electroCore, Inc. Launches Truvaga Plus on Amazon to Enhance Consumer Wellness Experience.
- Jun 12, 2024: Raised $7.8M
- Aug 08, 2023: Raised $52K in Series pre-seed
- Aug 08, 2023: Raised $750K in Series seed
- Oct 04, 2021: Raised $192K in Series pre-seed
See plans & pricing → Track electroCore’s funding, hiring, and signals — with verified contacts — on Fundz.